替奈普酶0.6 mg/kg治疗发病时间不明卒中的随机对照试验
本研究评估低剂量阿替普酶0.6 mg/kg对发病时间不明且FLAIR阴性的急性缺血性卒中是否有效安全。因WAKE-UP试验阳性结果提前终止,仅纳入131例。结果显示阿替普酶组与对照组90天良好预后无差异,症状性颅内出血和死亡安全性相当,但提前终止限制确定性结论。
要点
- 低剂量阿替普酶0.6 mg/kg对发病时间不明卒中未显示优于标准治疗。
- 良好预后(90天mRS 0-1)两组分别为47.1%和48.3%,无统计学差异。
- 症状性颅内出血和90天死亡在两组间无显著差异。
核心结论
- 在发病时间不明的缺血性卒中患者中,阿替普酶0.6 mg/kg组与对照组90天良好预后无差异。
- 阿替普酶0.6 mg/kg的安全性(症状性颅内出血和死亡)与标准治疗相当。
- 研究提前终止,无法得出确定性结论。
研究设计与样本
- 研究者发起的多中心、随机、开放标签、盲法终点试验。
- 纳入标准除最后已知良好时间>4.5小时外符合静脉溶栓标准,且MRI DWI显示急性缺血灶而FLAIR无显著对应高信号。
- 计划样本量300例,实际因WAKE-UP试验阳性提前终止,纳入131例(55例女性,平均年龄74.4±12.2岁)。
- 随机1:1分配至阿替普酶0.6 mg/kg组或标准药物治疗组。
- 主要结局为90天改良Rankin量表评分0-1分的良好预后。
主要发现
- 良好预后在阿替普酶组为32/68(47.1%),对照组为28/58(48.3%),相对风险0.97(95%CI 0.68-1.41),P=0.892。
- 22至36小时内症状性颅内出血在阿替普酶组为1/71,对照组为0/60,相对风险无穷大(95%CI 0.06至无穷大),P>0.999。
- 90天死亡在阿替普酶组为2/71,对照组为2/60,相对风险0.85(95%CI 0.06-12.58),P>0.999。
临床怎么用
- 对于发病时间不明且MRI显示DWI阳性/FLAIR阴性的缺血性卒中患者,低剂量阿替普酶0.6 mg/kg未显示优于标准治疗,临床决策需结合其他证据。
- 该研究因提前终止效力不足,不能据此否定低剂量阿替普酶的疗效,应参考WAKE-UP等试验结果。
局限性
- 研究因WAKE-UP试验阳性结果提前终止,仅纳入131/300例,样本量不足,统计效能低。
- 开放标签设计可能引入偏倚,尽管采用盲法终点评估。
- 提前终止 preclude 任何确定性结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- We assessed whether lower-dose alteplase at 0.6 mg/kg is efficacious and safe for acute fluid-attenuated inversion recovery-negative stroke with unknown time of onset. Methods- This was an investigator-initiated, multicenter, randomized, open-label, blinded-end point trial. Patients met the standard indication criteria for intravenous thrombolysis other than a time last-known-well >4.5 hours (eg, wake-up stroke). Patients were randomly assigned (1:1) to receive alteplase at 0.6 mg/kg or standard medical treatment if magnetic resonance imaging showed acute ischemic lesion on diffusion-weighted imaging and no marked corresponding hyperintensity on fluid-attenuated inversion recovery. The primary outcome was a favorable outcome (90-day modified Rankin Scale score of 0-1). Results- Following the early stop and positive results of the WAKE-UP trial (Efficacy and Safety of MRI-Based Thrombolysis in Wake-Up Stroke), this trial was prematurely terminated with 131 of the anticipated 300 patients (55 women; mean age, 74.4±12.2 years). Favorable outcome was comparable between the alteplase group (32/68, 47.1%) and the control group (28/58, 48.3%; relative risk [RR], 0.97 [95% CI, 0.68-1.41]; P=0.892). Symptomatic intracranial hemorrhage within 22 to 36 hours occurred in 1/71 and 0/60 (RR, infinity [95% CI, 0.06 to infinity]; P>0.999), respectively. Death at 90 days occurred in 2/71 and 2/60 (RR, 0.85 [95% CI, 0.06-12.58]; P>0.999), respectively. Conclusions- No difference in favorable outcome was seen between alteplase and control groups among patients with ischemic stroke with unknown time of onset. The safety of alteplase at 0.6 mg/kg was comparable to that of standard treatment. Early study termination precludes any definitive conclusions. Registration- URL: https://www.clinicaltrials.gov; Unique identifier: NCT02002325.
引用
- Koga M, Yamamoto H, Inoue M, et al. Thrombolysis With Alteplase at 0.6 mg/kg for Stroke With Unknown Time of Onset: A Randomized Controlled Trial. Stroke. 2020. PMID: 32248771. doi:10.1161/STROKEAHA.119.028127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。